Definium Therapeutics (DFTX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Definium Therapeutics held $1.05 billion in cash on Sept. 30, 2026. Management expects cash resources to fund planned operations into 2030.…

Definium Therapeutics NASDAQ: DFTX plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase…

Definium Therapeutics, Inc. reported strong Phase 3 results for DT120 in both GAD and MDD, positioning for an NDA filing in H1 2026. DFTX holds over $1bn in cash, supporting operations into 2030, and is preparing for a p…

Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript…

Definium Therapeutics NASDAQ: DFTX plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized an…

NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address …

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended …

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underly…

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

Shares of Definium Therapeutics, Inc. (NASDAQ: DFTX - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-one brokerages that are presently covering the company, Marketbeat.com reports. One…

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

Definium Therapeutics (NASDAQ: DFTX) Chief Medical Officer Dan Karlin said the company's recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder, or GAD, and major…

Definium Therapeutics (NASDAQ: DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment …

DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.…

Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript…

Definium Therapeutics (DFTX) has seen a significant rise in its stock price following the announcement of positive topline results from its Phase 3 Panorama stu…

Definium Therapeutics Inc. (NASDAQ:DFTX) on Monday released topline results from Panorama, its second Phase 3 study evaluating DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disor…

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underly…

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of p…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

